CCL11 and Huntington disease: There was a statistically significant difference in the mRNA expression of CCL11 among QFT-GIT test response groups in HD patients (p = 0.041), for which the expression levels in the >0.7 IU/mL response group were higher than those of the other two groups (Figure 3g).